Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
PEGS Boston SummitPEGS Boston Summit
Not Confirmed
Not Confirmed
11 May-15 November, 2026
ASCO Annual meetingASCO Annual meeting
Not Confirmed
Not Confirmed
29 May-02 June, 2026
Not Confirmed
Not Confirmed
01-03 June, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
PEGS Boston Summit
Not Confirmed
Contact SupplierPEGS Boston Summit
PEGS Boston SummitPEGS Boston Summit
Industry Trade Show
Not Confirmed
11 May-15 November, 2026
ASCO Annual meetingASCO Annual meeting
Industry Trade Show
Not Confirmed
29 May-02 June, 2026
Industry Trade Show
Not Confirmed
01-03 June, 2026
Digital content
NEWS #PharmaBuzz
25 Nov 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/lexogen-successfully-completes-large-scale-human-primary-cell-next-gen-sequencing-project-with-ochre-bio-302624463.html
20 Oct 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/new-nyc-liver-icu-lab-transforming-liver-disease-treatments-302589068.html
12 Jun 2024
// Annalee Armstrong FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/gsk-signs-ai-pact-ochre-pinpoint-source-liver-diseases
https://www.ochre-bio.com/2024/04/22/ochre-bio-announces-partnership-with-boehringer-ingelheim-to-develop-novel-regenerative-treatments-for-patients-with-advanced-liver-disease/
22 Apr 2024
// BUSINESSWIRE
16 May 2023
// BUSINESSWIRE
Drugs in Development
Details:
Ochre and GSK will create a foundational liver biology dataset that could have the potential to further improve translation of novel therapies for liver diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Undisclosed
Sponsor: GSK
Deal Size: $37.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 12, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Discovery Platform
Partner/Sponsor/Collaborator : GSK
Deal Size : $37.5 million
Deal Type : Licensing Agreement
GSK Enters Multi-Year Data Licence Agreement with Ochre Bio for Liver Disease Research
Details : Ochre and GSK will create a foundational liver biology dataset that could have the potential to further improve translation of novel therapies for liver diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 12, 2024
Details:
The partnership focuses on discovering first-in-class regenerative treatments for chronic liver diseases like metabolic dysfunction-associated cirrhosis.
Lead Product(s): Undisclosed
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Undisclosed
Sponsor: Boehringer Ingelheim GmbH
Deal Size: $1,035.0 million Upfront Cash: $35.0 million
Deal Type: Partnership April 22, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Discovery
Partner/Sponsor/Collaborator : Boehringer Ingelheim GmbH
Deal Size : $1,035.0 million
Deal Type : Partnership
Ochre Bio Partners with Boehringer Ingelheim for Advanced Liver Disease Treatments
Details : The partnership focuses on discovering first-in-class regenerative treatments for chronic liver diseases like metabolic dysfunction-associated cirrhosis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $35.0 million
April 22, 2024
Details:
Proceeds will support the development of first candidates for IND-enabling studies, as well as expand discovery and RNA chemistry capabilities to address a wider set of serious liver-related diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Undisclosed
Sponsor: Khosla Ventures
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing October 10, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Khosla Ventures
Deal Size : $30.0 million
Deal Type : Series A Financing
Details : Proceeds will support the development of first candidates for IND-enabling studies, as well as expand discovery and RNA chemistry capabilities to address a wider set of serious liver-related diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 10, 2022
Details:
Funding will be used to develop RNA therapies for transplant and chronic liver diseases. Ochre Bio has built a deep phenotyping platform to identify novel liver targets, validated directly in discarded human livers kept alive on machines.
Lead Product(s): Undisclosed
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Undisclosed
Sponsor: Khosla Ventures
Deal Size: $9.6 million Upfront Cash: Undisclosed
Deal Type: Financing June 16, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Khosla Ventures
Deal Size : $9.6 million
Deal Type : Financing
Ochre Bio Closes $9.6M Seed Financing Led by Khosla Ventures
Details : Funding will be used to develop RNA therapies for transplant and chronic liver diseases. Ochre Bio has built a deep phenotyping platform to identify novel liver targets, validated directly in discarded human livers kept alive on machines.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 16, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
